COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Curcumin Bioavailability in Glioblastoma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01712542
Recruitment Status : Completed
First Posted : October 23, 2012
Last Update Posted : June 4, 2013
Information provided by (Responsible Party):
Stephan Dützmann, Johann Wolfgang Goethe University Hospital

Brief Summary:
Measuring the bioavailability of orally administered curcumin in the tumors of glioblastoma patients.

Condition or disease
Patient Harboring Glioblastoma That Will Undergo Surgery

Layout table for study information
Study Type : Observational
Estimated Enrollment : 15 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measurement of Intratumoral Concentration of the Nontoxic Natural Compound Curcumin in Glioblastoma Patients
Study Start Date : October 2012
Actual Primary Completion Date : May 2013
Actual Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Concentration of Curcumin in Glioblastoma [ Time Frame: At Tumor resection ]
    At the time of surgery

Biospecimen Retention:   Samples Without DNA
Tumor tissue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients harboring Glioblastoma

Inclusion Criteria:

  • Patients harboring Glioblastoma
  • Patient will undergo surgery

Exclusion Criteria:

  • BMI > 30
  • Liver and Kidney Function so compromised that medication is prescribed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01712542

Layout table for location information
Department of Neurosurgery, Johann Wolfgang Goethe-University
Frankfurt, Hessen, Germany, 60528
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospital
Layout table for investigator information
Principal Investigator: Stephan Duetzmann Goethe University
Layout table for additonal information
Responsible Party: Stephan Dützmann, M.D., Johann Wolfgang Goethe University Hospital Identifier: NCT01712542    
Other Study ID Numbers: JohannWGUH_Curcumin-01
First Posted: October 23, 2012    Key Record Dates
Last Update Posted: June 4, 2013
Last Verified: June 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue